The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Isolation of Human Intestinal Bacteria Capable of Producing the Bioactive Metabolite Isourolithin A from Ellagic Acid
Open accessAbstract
Urolithins are intestinal microbial metabolites produced from ellagitannin- and ellagic acid-containing foods such as walnuts, strawberries, and pomegranates. These metabolites, better absorbed than their precursors, can contribute significantly to the beneficial properties attributed to the polyphenols ellagitannins and ellagic acid (EA). However, both the ability of producing the final metabolites in this catabolism (urolithins A, B and isourolithin A) and the health benefits associated with ellagitannin consumption differ considerably among individuals depending on their gut microbiota composition. Three human urolithin metabotypes have been previously described, i.e., metabotype 0 (urolithin non-producers), metabotype A (production of urolithin A as unique final urolithin) and metabotype B (urolithin B and/or isourolithin A are produced besides urolithin A). Although production of some intermediary urolithins has been recently attributed to intestinal species from Eggerthellaceae family named Gordonibacter urolithinfaciens and Gordonibacter pamelaeae, the identification of the microorganisms responsible for the complete transformation of EA into the final urolithins, especially those related to metabotype B, are still unknown. In the present research we illustrate the isolation of urolithin-producing strains from human feces of a healthy adult and their ability to transform EA into different urolithin metabolites, including isourolithin A. The isolates belong to a new genus from Eggerthellaceae family. EA transformation and urolithin production arisen during the stationary phase of the growth of the bacteria under anaerobic conditions. The HPLC-DAD-MS analyses demonstrated the sequential appearance of 3,8,9,10-tetrahydroxy-urolithin (urolithin M6), 3,8,9-trihydroxy-urolithin (urolithin C) and 3,9-dihydroxy-urolithin (isourolithin A) while 3,8-dihydroxy-urolithin (urolithin A) and 3-hydroxy-urolithin (urolithin B) were not detected. For the first time isourolithin A production capacity of pure strains has been described. The biological activity attributed to urolithins A and B and isourolithin A (anti-inflammatory, anti-carcinogenic, cardioprotective and neuroprotective properties) explains the relevance of identifying these urolithin-producing bacteria as potential novel probiotics with applications in the development of functional foods and nutraceuticals. Their human administration could improve the health benefits upon ellagitannin consumption, especially in metabotype 0 individuals. However, further research is necessary to probe well established beneficial effects on the host and safety requirements before being considered among the next-generation probiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of Protein Molecules
JUKES, T. H., & CANTOR, C. R. (1969) · Mammalian Protein Metabolism · doi:10.1016/b978-1-4832-3211-9.50009-7 · Cited by 11,032
Akkermansia muciniphila and its role in regulating host functions
Derrien, M., Belzer, C., & de Vos, W. M. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.02.005 · Cited by 1,044 · cited 1×
“In addition to the classical probiotics (Lactobacillus and Bifidobacterium), other beneficial microbiota such as the butyrate-producing Faecalibacterium prausnitzii (Eppinga et al., 2016) and the mucin-degrading Akkermansia muciniphila (Derrien et al., 2016) have recently been described.”
BackgroundSelma, M. V., Beltrán, D., García-Villalba, R., Espín, J. C., & Tomás-Barberán, F. A. (2014) · Food Funct. · doi:10.1039/c4fo00092g · Cited by 304
Self-citationGonzález‐Sarrías, A., Giménez‐Bastida, J. A., García‐Conesa, M. T., Gómez‐Sánchez, M. B., García‐Talavera, N. V., Gil‐Izquierdo, A., Sánchez‐Álvarez, C., Fontana‐Compiano, L. O., Morga‐Egea, J. P., Pastor‐Quirante, F. A., et al. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900152 · Cited by 212
Self-citationMatthies, A., Clavel, T., Gütschow, M., Engst, W., Haller, D., Blaut, M., & Braune, A. (2008) · Applied and Environmental Microbiology · doi:10.1128/aem.00555-08 · Cited by 141
Cited by
The effects of polyphenols and other bioactives on human health
Fraga, C. G., Croft, K. D., Kennedy, D. O., & Tomás-Barberán, F. A. (2019) · Food & Function · doi:10.1039/c8fo01997e · Cited by 1,126
Self-citationThe gut microbiome as a modulator of healthy ageing
Ghosh, T. S., Shanahan, F., & O’Toole, P. W. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00605-x · Cited by 817
Bioactivity of dietary polyphenols: The role of metabolites
Luca, S. V., Macovei, I., Bujor, A., Miron, A., Skalicka-Woźniak, K., Aprotosoaie, A. C., & Trifan, A. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1546669 · Cited by 718
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01406-7 · Cited by 359
Catalkaya, G., Venema, K., Lucini, L., Rocchetti, G., Delmas, D., Daglia, M., De Filippis, A., Xiao, H., Quiles, J. L., Xiao, J., et al. (2020) · Food Frontiers · doi:10.1002/fft2.25 · Cited by 328
Metadata
- Authors
- Selma, M. V., Beltrán, D., Luna, M. C., Romo-Vaquero, M., García-Villalba, R., Mira, A., Espín, J. C., & Tomás-Barberán, F. A.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2017-08-07
- Volume
- 8
- Pages
- 1521-1521
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W2739848673
- Cited by
- 211
- References
- 5
- FWCI
- 10.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.